Should You Buy Vertex Pharmaceuticals Inc (VRTX) Today? Analysis, Price Targets, and 2026 Outlook.
No data
No data
Growth
Profitability
Efficiency
Wall Street analysts forecast VRTX stock price to rise
22 Analyst Rating
Wall Street analysts forecast VRTX stock price to rise
17 Buy
5 Hold
0 Sell
Strong Buy
Current: 447.970
Low
414
Averages
515.88
High
604
Current: 447.970
Low
414
Averages
515.88
High
604
Truist
NULL
to
Buy
initiated
$525 -> $542
AI Analysis
2026-05-27
New
Reason
Truist
Price Target
$525 -> $542
AI Analysis
2026-05-27
New
initiated
NULL
to
Buy
Reason
Truist assumed coverage of Vertex Pharmaceuticals with a Buy rating and price target of $542, up from $525. The firm believes Vertex's emerging kidney franchise can grow into blockbuster assets and further diversify the company's product portfolio.
Barclays
NULL -> Overweight
maintain
$607 -> $615
2026-05-06
Reason
Barclays
Price Target
$607 -> $615
2026-05-06
maintain
NULL -> Overweight
Reason
Barclays raised the firm's price target on Vertex Pharmaceuticals to $615 from $607 and keeps an Overweight rating on the shares.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for VRTX
